Amylyx Pharmaceuticals, Inc. - AMLX
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| May 15, 2026 | SCHEDULE 13G/A | Perceptive Advisors LLC | 7.5% | 8,284,882 | View |
| May 15, 2026 | SCHEDULE 13G/A | Joseph Edelman | 7.5% | 8,284,882 | View |
| May 15, 2026 | SCHEDULE 13G/A | Perceptive Life Sciences Master Fund, Ltd. | 7.5% | 8,284,882 | View |
| Mar 26, 2026 | SCHEDULE 13G/A | The Vanguard Group | 0.0% | 0 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TCG Crossover GP II, LLC | 5.7% | 6,243,812 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | TCG Crossover Fund II, L.P. | 5.7% | 6,243,812 | View |
| Feb 17, 2026 | SCHEDULE 13G/A | Chen Yu | 5.7% | 6,243,812 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Adage Capital Management, L.P. | 2.53% | 2,777,055 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Robert Atchinson | 2.53% | 2,777,055 | View |
| Feb 12, 2026 | SCHEDULE 13G/A | Phillip Gross | 2.53% | 2,777,055 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | FMR LLC | 15.0% | 16,468,419 | View |
| Feb 05, 2026 | SCHEDULE 13G/A | Abigail P. Johnson | 15.0% | 16,468,419 | View |
| Jan 30, 2026 | SCHEDULE 13G | The Vanguard Group | 5.28% | 5,804,912 | View |
| Jan 21, 2026 | SCHEDULE 13G/A | BlackRock, Inc. | 7.1% | 7,783,648 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.